Definitive Healthcare (NASDAQ:DH) Issues Q2 2026 Earnings Guidance
by Jessica Moore · The Cerbat GemDefinitive Healthcare (NASDAQ:DH – Get Free Report) issued an update on its second quarter 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.030-0.040 for the period, compared to the consensus earnings per share estimate of 0.030. The company issued revenue guidance of $55.0 million-$56.0 million, compared to the consensus revenue estimate of $55.7 million. Definitive Healthcare also updated its FY 2026 guidance to 0.160-0.19 EPS.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on DH shares. Wall Street Zen raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definitive Healthcare in a research note on Wednesday, January 21st. Canaccord Genuity Group decreased their target price on Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating on the stock in a research note on Friday, February 27th. Barclays dropped their target price on Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating for the company in a research report on Monday, March 30th. Finally, Stephens lowered their price objective on shares of Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.27.
Get Our Latest Report on Definitive Healthcare
Definitive Healthcare Stock Down 2.4%
NASDAQ DH traded down $0.02 on Thursday, hitting $0.92. 331,909 shares of the stock were exchanged, compared to its average volume of 354,274. Definitive Healthcare has a fifty-two week low of $0.90 and a fifty-two week high of $4.70. The company has a 50-day moving average price of $1.10 and a 200-day moving average price of $1.99. The company has a market cap of $97.23 million, a PE ratio of -0.74, a PEG ratio of 84.12 and a beta of 1.34. The company has a quick ratio of 1.64, a current ratio of 1.64 and a debt-to-equity ratio of 0.41.
Definitive Healthcare (NASDAQ:DH – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. Definitive Healthcare had a negative net margin of 57.52% and a positive return on equity of 2.63%. The firm had revenue of $55.93 million during the quarter, compared to the consensus estimate of $55.02 million. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. Sell-side analysts anticipate that Definitive Healthcare will post 0.01 EPS for the current fiscal year.
Institutional Trading of Definitive Healthcare
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC grew its stake in shares of Definitive Healthcare by 56.7% in the 1st quarter. AQR Capital Management LLC now owns 590,149 shares of the company’s stock valued at $1,706,000 after purchasing an additional 213,562 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Definitive Healthcare by 564.2% during the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock worth $25,191,000 after purchasing an additional 7,404,363 shares during the period. Jane Street Group LLC lifted its holdings in shares of Definitive Healthcare by 166.0% during the first quarter. Jane Street Group LLC now owns 105,114 shares of the company’s stock worth $304,000 after purchasing an additional 65,597 shares during the period. Creative Planning grew its position in Definitive Healthcare by 41.7% in the 2nd quarter. Creative Planning now owns 28,628 shares of the company’s stock valued at $112,000 after buying an additional 8,428 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new position in Definitive Healthcare in the 2nd quarter valued at $4,247,000. Institutional investors and hedge funds own 98.67% of the company’s stock.
Definitive Healthcare Company Profile
Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.
The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.